Clinical trial
Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer
NCT00298155 · University of Washington, Other · Completed
Key facts
| NCT number | NCT00298155 |
|---|---|
| Title | Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer |
| Official title | Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer |
| Acronym | TAPS |
| Lead sponsor | University of Washington, Other |
| Collaborators | GlaxoSmithKline Industry AstraZeneca |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer, Prostate Neoplasms |
| Intervention type | Drug |
| Interventions | goserelin with dutasteride, goserelin with bicalutamide and dutasteride, goserelin with bicalutamide and dutasteride and ketoconazole |
| Enrollment | 35 |
| Start date | Jul 1, 2006 |
| Primary completion | Jun 1, 2010 |
| Completion | Jan 1, 2014 |
| First posted | Mar 1, 2006 |
| Last update posted | Aug 9, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: